Development of a meningococcal disease vaccine based on heat shock protein complexes
Start a new DMP in Loading
There is an urgent need for an effect vaccine to prevent serogroup B meningococcal disease. This causes about 1200-1500 cases of disease with about 100 deaths per year in the UK, with many more deaths worldwide. To date scientists have not been able to develop a vaccine that can protect against all the strains that cause disease. This vaccine, based on heat shock protein complexes presents a wide range of parts of the bacterium to the human immune system in a very effective way, offering the potential for cross strain protection. This proposal is to develop a manufacturing process for the vaccine so it can be made in the quantity and manner to be suitable for injection into large numbers of children.
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=ukri________::c65406ba5590fdc4141c7e0cacc00c88&type=result"></script>');
-->
</script> For further information contact us at helpdesk@openaire.eu